Predictive Modeling of Phenylpiperazine Derivatives for Renin Inhibition QSAR Study of Phenylpiperazine Derivatives as Renin Inhibitors
Iranian Journal of Pharmaceutical Sciences,
Vol. 14 No. 1 (2018),
15 January 2018
,
Page 15-26
https://doi.org/10.22037/ijps.v14.40668
Abstract
The renin–angiotensin–aldosterone system is the well-established endocrine system having significant role in preserving hemodynamic stability. Renin is secreted from the juxtaglomerular cells of the kidney. Phenylpiperazine derivatives have been reported as human renin inhibitor. To do the study, a predictive QSAR modeling for 27 phenylpiperazine derivatives as renin enzyme inhibitors was used. The IC50 values for purified human renin were taken as biological activity. Physicochemical properties were calculated on Dragon software, version 5.5. Hierarchical Multiple Regression was performed to obtain quantitative structure-activity relationship model which again validated internally and externally. The selected best QSAR model had the correlation coefficient (R2) of 0.843, and predicted correlation coefficient (R2pred) of 0.867. The predictive ability of the selected model was established by leaving one-out cross-validation. Different Rm2 matrices were also calculated to validate the model externally. The quantitative structure activity relationship study indicates that CIC2, BIC2, and R7v descriptors have a very important role in renin enzyme and ligand interaction. The developed model can be applied to design new effective renin enzyme inhibitors.
- Complementary Information Content index
- GATEWAY
- Juxtaglomerular cell tumor
- Novel descriptors For „Renin’ binding
- ‘Phenylpiperazine’
- QSAR
- Treatment of hypertension
- Wilms' tumor
How to Cite
References
[2] Zaman MA, Oparil S, Calhoun DA. Drugs targeting the renin-angiotensin-aldosterone system. Nat Rev Drug Discovery (2002) 1(8): 621–636.
[3] Schmieder RE, Hilgers KF, Schlaich MP, Schmidt BMW. Renin-angiotensin system and cardiovascular risk. Lancet (2007) 369(9568): 1208–1219
[4] okokawa F, Maibaum J. Recent advances in the discovery of non-peptidic direct renin inhibitors as antihypertensives: new patent applications in years 2000–2008. Expert Opin Ther Pat (2008) 18(6): 581–602.
[5] Weber MA. Clinical experience with the angiotensin II receptor antagonist losartan. A preliminary report. Am J Hypertens (1992) 5(12 Pt 2): 247S-251S.
[6] Norris K, Vaughn C. The role of renin-angiotensin-aldosterone system inhibition in chronic kidney disease. Expert Rev Cardiovasc Ther (2003) 1(1): 51-63.
[7] Cooper ME. The role of the renin-angiotensin-aldosterone system in diabetes and its vascular complications. Am J Hypertens (2004) 17(11 Pt 2): 16S-20S.
[8] Daugherty KK. Aliskiren. Am J Health Syst Pharm (2008) 65(14): 1323–1332.
[9] Jensen C, Herold P, Brunner HR. Aliskiren: the first renin inhibitor for clinical treatment. Nat Rev Drug Discov (2008) 7(5): 399–410.
[10] Holsworth DD, Cai C, Cheng XM, Cody WL, Downing DM, Erasga N, Lee C, Powell NA, Edmunds JJ, Stier M, Jalaie M, Zhang E, McConnell P, Ryan MJ, Bryant J, Li T, Kasani A, Hall E, Subedi R, Rahim M, Maiti S. Keto Piperazine-based Renin inhibitors: Optimization of the “C” ring. Bio & Med Chem Lett (2006) 16(9): 2500-2504.
[11] Holsworth DD, Powell NA, Downing DM, Cai C, Cody WL, Ryan M, Ostroski R, Jalaie M, Bryant JW, Edmunds JJ. Discovery of novel non-peptidic Keto Piperazine-based Renin inhibitors. Bio & Med Chem (2005) 13(7): 2657-2664.
[12] Bezencon O, Bur D, Weller T, Bildstein SR, Remen L, Stifferlen T, Corminboeuf O, Grisostomi C, Boss C, Prade L, Delahaye S, Treiber A, Strickner P, Binkert C, Hess P, Steiner B, Fischli W. Design and preparation of potent, nonpeptidic, bioavailable Renin inhibitors. J Med Chem (2009) 52(12): 3689-3702.
[13] Nabata H, Aono J, Ishizuka N, Sakai K. Antihypertensive effects of a novel phenylpiperazine derivative, SGB-1534, on several hypertensive models of rats. Arch Int Pharmacodyn Ther (1985) 277(1): 104-118.
[14] Ma TK, Kam KK, Yan BP, Lam YY. Renin-angiotensin-aldosterone system blockade for cardiovascular diseases: current status. Br J Pharmacol (2010) 160(6): 1273-1292.
[15] Patel JR, Prajapati LM. Development and Validation of a Robust QSAR Model for Piperazine and Keto Piperazine Derivatives as Renin Inhibitors. Open Pharmaceutical Sciences Journal (2016) 3(1): 1-24.
[16] Nakamura Y, Fujimoto T, Ogawa Y, Namiki H, Suzuki S, Asano M, Sugita C, Mochizuki A, Miyazaki S, Tamaki K, Nagai Y, Inoue S, Nagayama T, Kato M, Chiba K, Takasuna K, Nishi T. Lead optimization of 5-amino-6-(2,2-dimethyl-5-oxo-4-phenylpiperazin-1-yl)-4-hydroxyhexanamides to reduce a cardiac safety issue: discovery of DS-8108b, an orally active renin inhibitor. Bioorg Med Chem (2013) 21(11): 3175-3196.
[17] CS Chem Office, Version 8.0, Cambridge Soft Corporation, Software Publishers Association, 1730 M Street, NW, Suite 700, Washington, D.C. 20036.
[18] DRAGON for Windows, ver.5.5, Talete srl, Milano, Italy 2007.
[19] Gupta AK, Arockia BM, Kaskhedikar SG. VALSTAT, Validation Program for Quantitative Structure Activity Relationship studies. Ind J Pharm Sci (2004) 66(4): 396-402.
[20] Ojha PK, Mitra I, Das RN, Roy K. Further exploring rm2 metrics for validation of QSPR models. Chem & Int Laboratory Sys (2011) 107(1): 194-205.
[21] Roy K, Mitra I, Kar S, Ojha PK, Das RN, Kabir H.Comparative studies on some metrics for external validation of QSPR models. J Chem Inf Model (2012) 52(2): 396-408.
[22] Patel JR, Prajapati LM. Predictive QSAR modeling on tetrahydropyrimidine-2-one derivatives as HIV-1 protease enzyme inhibitors. Med Chem Res (2013) 22(6): 2795-2801.
[23] Prajapati LM, Patel MJ, Parmar VK, Patel JR. Development of QSAR model for prediction of fold selectivity of phenyl benzoxazole as estrogen receptor inhibitors. Med Chem Res (2012) 21(11): 3681–3686.
[24] Prajapati LM, Parmar VK, Patel MJ, Patel JR. Development of QSAR model for indoyl aryl sulfone derivatives as reverse transcriptase inhibitors. Der pharma chem (2011) 3(6): 53-61.
[25] Prajapati LM, Patel JR, Parmar VK. Descriptors requirement for QSAR analysis of pyrazolo-triazolo-pyrimidine derivative as human A3 receptor antagonists: design of novel furan derivatives and validation by docking. Med Chem Res (2014) 23(5): 2554-2563.
[26] Dulin F, Halm-Lemeille MP, Lozano S, Lepailleur A, Santos JS, Rault S, Bureau R. Interpretation of honeybees contact toxicity associated to acetylcholinesterase inhibitors. Ecotoxicol Environ Saf (2012) 79: 13-21.
[27] Duda-Seiman C, Duda-Seimana D, Putz MV, Ciubotariub D. Qsar Modelling Of Anti-Hiv Activity With Hept Derivatives. Dig J Nanomater Biostruct (2007) 2(2): 207 – 219.
[28] Todeschini R, Consonni V. Handbook of Molecular Descriptors: Methods and Principles in Medicinal Chemistry, Wiley-VCH: Weinheim, Germany (2008).
- Abstract Viewed: 309 times
- IJPS_Volume 14_Issue 1_Pages 15-26 Downloaded: 275 times